We are live on ! Find out more

Can-Fite BioPharma American Depositary Shares

CANF

Market cap $4.94M

1.63 USD

+0.01

0.62%

At close Updated Nov 2, 4:00 PM EST

Pre-market

After hours

1.69

+0.06

3.68%

1 day

0.62%

5 days

-1.21%

1 month

-25.23%

3 months

-48.58%

6 months

-50.9%

Year to date

-62.95%

1 year

-80.22%

5 years

-99.46%

10 years

-99.98%

About: Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

Employees: 5

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 10%

Neutral 90%

Negative 0%

Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome

Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat Gan, Israel, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Eurasian Patent Office (EAPO) has issued a notification of readiness to grant a patent covering the use of Piclidenoson for the treatment of diseases associated with OCRL deficiency, including Lowe syndrome and Dent disease 2.

Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome

Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026

Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39 months and overall survival exceeding 20.7 months RAMAT GAN, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing small molecule therapeutics targeting cancer and inflammatory diseases, today announced the presentation of final positive data from its Phase IIa clinical study of namodenoson in advanced pancreatic ductal adenocarcinoma at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise price of $5.00 per ADS, issued by Can-Fite in March 2026, at a reduced exercise price of $2.50 per ADS. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form F-3 (File No. 333-294760). The closing of the offering is expected to occur on or about September 3, 2026, subject to satisfaction of customary closing conditions.

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer.

Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today provided an update on the regulatory status of its two lead drug candidates, Piclidenoson and Namodenoson.

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the submission of a Phase 2 clinical study protocol to Bambino Gesù Children's Hospital in Rome, Italy, for the first clinical evaluation of Piclidenoson in patients with Lowe syndrome, a rare inherited genetic disorder with no approved disease-modifying therapies.

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

See News Rankings

Price charts implemented using Lightweight Charts™